Perspectives Of New Serum Markers For Biochemical Screening In Pregnancy
The benefit of detecting chromosomal anomalies before birth is nowadays widely acknowledged. As a result screening programs have been established in many countries in which the risk of chromosomal abnormalities is calculated for every pregnancy. There are some data about application of maternal serum inhibin A as Down syndrome and pre-eclampsia marker. The focus is thus on new early markers. In this paper a new maternal serum markers (PP13 and ADAM-12) and their applications are surveyed.